Clinical Efficacy and Effect on Inflammatory Cytokines of Huangjin Shuangshen Jiawei Granules in Treating Patients with Postoperative Anxiety and Depression After PCI for Coronary Heart Disease
10.13422/j.cnki.syfjx.20241223
- VernacularTitle:黄金双参加味颗粒干预冠心病PCI术后焦虑抑郁障碍患者的临床疗效及对炎症因子的影响
- Author:
Muchen ZHANG
1
;
Yuchen SUN
1
;
Yaqin WANG
1
;
Shujun ZHAO
1
;
Sanchun TANG
1
;
Ju YIN
1
;
Yilin ZHAO
1
;
Yan ZHANG
2
Author Information
1. Liaoning University of Traditional Chinese Medicine（TCM）， Shenyang 110847， China
2. The Affiliated Hospital of Liaoning University of TCM， Shenyang 110000， China
- Publication Type:Journal Article
- Keywords:
Huangjin Shuangshen Jiawei granules;
after percutaneous coronary intervention （PCI） for coronary heart disease;
anxiety and depression;
inflammatory cytokine;
syndrome of stasis and toxin stagnation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(21):138-144
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the clinical efficacy of Huangjin Shuangshen Jiawei （HJSSJW） granules in treating postoperative anxiety and depression after percutaneous coronary intervention （PCI） for coronary heart disease and the effects of this medicine on inflammatory cytokines. MethodNinety-four patients diagnosed with anxiety and depression after PCI were randomized into observation and control groups （47 cases） by the double-blind method. On the basis of conventional Western medical treatment， the observation group was treated with HJSSJW granules for 12 weeks， and the control group with the simulant of HJSSJW granules for 12 weeks. The two groups were compared in terms of Hamilton Anxiety and Depression Scales （HAMA-14， HAMD-24）， Pittsburgh Sleep Quality Inventory （PSQI）， Seattle Angina Score （SAQ）， TCM symptom scores， traditional Chinese medicine （TCM） symptom score and response rate， serum levels of hypersensitive-C reactive protein （hs-CPR）， tumor necrosis factor （TNF）-α， and interleukin （IL-6）， and incidence of major adverse cardiovascular events （MACEs） and adverse reactions. ResultAfter treatment， both groups showed declined scores of HAMA-14， HAMD-24， and PSQI （P<0.05， P<0.01） and the observation group had lower scores of HAMA-14， HAMD-24， and PSQI than the control group （P<0.01）. The scores of SAQ in both groups increased after treatment （P<0.01）， and the observation group had higher score of each dimension than the control group （P<0.05）. The TCM symptom scores decreased in both groups after treatment （P<0.01）， and they were lower in the observation group than in the control group （P<0.05）. The total response rate regarding TCM symptoms in the observation group was higher than that in the control group （χ2=9.225， P<0.01）. After treatment， the levels of hs-CPR， IL-6， and TNF-α became lowered in both groups （P<0.01）， and the observation group had lower levels of hs-CPR， IL-6， and TNF-α than the control group （P<0.05）. The incidence of MACEs in the observation group was lower than that in the control group during the 90 d of the follow-up period （χ2=4.242， P<0.05）. No adverse reactions associated with the use of HJSSJW granules were observed during the trial period. ConclusionHJSSJW granules can alleviate the bad mood， improve sleep， mitigate somatic symptoms， improve the quality of life， reduce inflammatory damage， and improve prognosis， being safe for clinical use in patients with postoperative anxiety and depression after PCI for coronary heart disease.
